|
|
| Procainamide | ||
| Order Code: PA
Order Form: A-1a Therapeutic Drug Analysis or IPR Req |
Chemistry 6240 RCP 356-3527 |
|
Specimen |
Plasma | ||
Collection Medium: |
| ||
Alternate Collection Media: |
Call laboratory for additional acceptable specimen collection containers. | ||
Minimum: |
5 ml; light green top tube or one 0.6 ml microtube. | ||
Testing Schedule: |
24 hrs/day, 7 days a week, including holidays. | ||
Analytic Time: |
2 hours (upon receipt in laboratory) | ||
Reference Range: |
The parent drug, procainamide (PA) and n-acetyl metabolite are quantitated separately. N-acetyl procainamide (NAPA) will not be done unless specifically requested. NAPA is most useful in renal failure. Therapeutic range for procainamide is 4-10 mcg/mL with toxicity beginning at levels greater than 16 mcg/ml. | ||
Test Limitations: |
Icterus: No significant interference up to an I index of 60 (approximate bilirubin concentration: 60 mg/dl). Hemolysis: No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 1000 mg/dl). Lipemia (Intralipid): No significant interference from lipemia up to an L index of 1000. (approximate triglycerides concentration: 2000 mg/dl). No significant interference from total protein up to 13 g/dl. No significant interference from rheumatoid factors up to 66 IU/ml. As with any assay employing mouse antibodies, the possibility exists for interference by human anti-mouse antibodies (HAMA) in the sample, which could cause falsely elevated results. The incidence of patients with antibodies to E. coli beta-galactosidase is extremely low. However, some samples containing such antibodies can result in artificially high procainamide results that do not fit the clinical profile. | ||
Methodology: |
Photometric Assay | ||
CPT Code: |
80190 | ||
See Additional Information: Chemistry Critical Lab Values |
Updated: 06/07/2007
Note: The information contained in this handbook is for use by personnel of University of Iowa Health Care. No other use is implied or intended.